Answers are grounded in this paper and cite their sources.
Background: Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe complication requiring early recognition and risk stratification. However, factors associated with prevalent disease, non-invasive detection, incident PAH, and prognosis after diagnosis are frequently conflated. Methods: PubMed, Web of Science, Scopus, and the Cochrane Library were initially searched through 23 September 2026, and searches of all four databases were updated on 1 November 2026. Observational evidence was evaluated using a structured clinical-pathway framework and the Newcastle–Ottawa Scale, and findings were synthesized narratively because of clinical and methodological heterogeneity and potentially overlapping cohorts. Results: Thirty-five studies were included in the qualitative synthesis. Serositis, interstitial lung disease, pericardial effusion, anti-U1 RNP and anti-Ro/SSA antibodies, reduced diffusing capacity, and microvascular abnormalities were mainly associated with prevalent or concomitant disease. Non-invasive detection was supported by a multimodal approach incorporating symptoms, biomarkers, pulmonary function, and echocardiography, with right heart catheterization required for PAH confirmation. Evidence on incident, catheterization-confirmed PAH prediction was limited. After diagnosis, functional class, exercise capacity, pulmonary vascular load, right-heart function, and serial risk status were recurrent prognostic indicators. Conclusions: Evidence is more extensive for prognosis after established SLE-PAH than for incident prediction, highlighting the need for externally validated SLE-specific screening and risk-stratification tools.
No takes yet. Share an insight, caveat, or question.
Radić et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: